Alpha Tau Medical Ltd.
DRTS
Positions held
Your positionsDRTS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Alpha Tau Medical Ltd. operates in the biotechnology sector, which is known for its potential to revolutionize healthcare through innovative therapies and treatments.
- The company's market capitalization stands at approximately $1.34 billion, indicating a significant presence in the healthcare market.
- Despite current challenges, the stock has a buy signal with a score of 18.00, suggesting potential for future growth.
- Alpha Tau Medical Ltd. has reported zero revenue for multiple quarters, indicating a lack of product sales and market traction.
- The company has consistently posted negative net income, with a loss of -45.813 million in Q2 2026.
- The forward P/E ratio is -27.09, reflecting negative earnings expectations and potential investor concerns.
Fundamentals
| Market cap | $1.29B | Enterprise value | $1.21B | Trailing P/E | — | Forward P/E | -26.19 |
| PEG | — | Price / book | 29.35 | Beta | 1.22 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -141.7% | ROA | -25.7% | Debt / equity | 0.34 |
| Current ratio | 11.09 | Free cash flow | -$20.26M | Analyst recommendation | none | Mean target | $17.80 |
| 52w high | $15.79 | 52w low | $3.43 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$45.8M | -$22.9M | -$12.1M | -$11.7M | -$10.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.8M | -$13.3M | -$12.6M | -$10.7M | -$9.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$42.6M | -$31.8M | -$29.2M | -$33.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.3M | -$36.0M | -$35.7M | -$32.1M | — |
Headlines — positive tone
• [OK · fundamentals] Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following
News
2026-10-05 · Alpha Tau to Participate in October Investor Conferences
2026-10-05 · Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher
2026-09-02 · Alpha Tau to Participate in September Investor Conferences
2026-08-31 · Alpha Tau Medical Completes Patient Enrollment in Pancreatic Cancer Study
2026-08-28 · ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
2026-08-17 · Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
2026-08-10 · Alpha Tau Medical Files for Dual Listing on Tel Aviv Stock Exchange
2026-08-01 · Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial
2026-07-15 · Alpha Tau Medical Treats First Immunocompromised Patient in Alpha DaRT Study
Price (daily)
Full chart · RSI · MACD · patterns